BR112014006684A2 - análogos de glucagon - Google Patents

análogos de glucagon

Info

Publication number
BR112014006684A2
BR112014006684A2 BR112014006684A BR112014006684A BR112014006684A2 BR 112014006684 A2 BR112014006684 A2 BR 112014006684A2 BR 112014006684 A BR112014006684 A BR 112014006684A BR 112014006684 A BR112014006684 A BR 112014006684A BR 112014006684 A2 BR112014006684 A2 BR 112014006684A2
Authority
BR
Brazil
Prior art keywords
glucagon peptides
glucagon
glucagon analogs
hyperglycemia
obesity
Prior art date
Application number
BR112014006684A
Other languages
English (en)
Portuguese (pt)
Inventor
Thogersen Henning
F Lau Jesper
Kresten Nielsen Peter
Kruse Thomas
Sensfuss Ulrich
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112014006684A2 publication Critical patent/BR112014006684A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
BR112014006684A 2011-09-23 2012-09-21 análogos de glucagon BR112014006684A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11182476 2011-09-23
US201161539148P 2011-09-26 2011-09-26
PCT/EP2012/068649 WO2013041678A1 (en) 2011-09-23 2012-09-21 Novel glucagon analogues

Publications (1)

Publication Number Publication Date
BR112014006684A2 true BR112014006684A2 (pt) 2017-03-28

Family

ID=47911932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006684A BR112014006684A2 (pt) 2011-09-23 2012-09-21 análogos de glucagon

Country Status (17)

Country Link
US (4) US8541368B2 (OSRAM)
EP (1) EP2758426B1 (OSRAM)
JP (2) JP6352806B2 (OSRAM)
KR (1) KR20140070612A (OSRAM)
CN (1) CN104093735B (OSRAM)
AR (1) AR088161A1 (OSRAM)
AU (1) AU2012311484B2 (OSRAM)
BR (1) BR112014006684A2 (OSRAM)
CA (1) CA2849673A1 (OSRAM)
IL (1) IL231199A0 (OSRAM)
IN (1) IN2014CN02448A (OSRAM)
MX (1) MX354705B (OSRAM)
MY (1) MY167234A (OSRAM)
RU (2) RU2017101333A (OSRAM)
TW (1) TWI596110B (OSRAM)
WO (1) WO2013041678A1 (OSRAM)
ZA (1) ZA201401603B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289560B1 (en) * 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
PL2986313T3 (pl) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
HRP20191258T1 (hr) * 2013-04-18 2019-10-18 Novo Nordisk A/S Stabilni, suagonisti receptora glp-1 i glukagonskog receptora s produljenim djelovanjem, namijenjeni upotrebi u medicini
MX2015016564A (es) 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
CA2926314C (en) 2013-10-17 2023-08-29 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
KR20160114082A (ko) * 2014-02-18 2016-10-04 노보 노르디스크 에이/에스 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
EP3204408B1 (en) 2014-10-10 2020-05-06 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017015538A1 (en) 2015-07-22 2017-01-26 Purdue Research Foundation Modified glucagon molecules
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
AU2017207862B2 (en) * 2016-01-13 2020-12-17 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
US11659854B2 (en) 2017-07-13 2023-05-30 Fuji Oil Holdings Inc. Method for imparting body taste to food
WO2019016306A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S BIFUNCTIONAL COMPOUNDS
US11357861B2 (en) 2017-09-29 2022-06-14 Hanmi Pharm. Co., Ltd Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US20220125885A1 (en) * 2019-02-05 2022-04-28 Eli Lilly And Company Glucagon analog agonists and methods of using the same
EP4076492A4 (en) * 2019-12-20 2024-01-17 Merck Sharp & Dohme LLC PCSK9 ANTAGONIST COMPOUNDS
TWI850611B (zh) * 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN113759048B (zh) * 2021-10-14 2022-06-21 成都普康唯新生物科技有限公司 一种十八烷二酸单叔丁酯检验方法

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
ZA90533B (en) 1989-02-01 1990-10-31 Shionogi & Co A method for the production of glucagon
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CN1202105A (zh) 1995-09-08 1998-12-16 诺沃挪第克公司 2－烷基吡咯烷化合物
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
ATE246190T1 (de) 1996-12-31 2003-08-15 Reddys Lab Ltd Dr Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE69727837T2 (de) 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
AU749271B2 (en) 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
DE69803750T2 (de) 1997-12-02 2002-09-12 Dr. Reddy's Research Foundation, Andhra Pradesh Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123268A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023415A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1140945B1 (en) 1998-12-18 2003-06-04 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
EP1147092A1 (en) 1999-01-18 2001-10-24 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000063193A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
AU3956900A (en) 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
BR0010683A (pt) 1999-04-16 2003-07-01 Reddy Research Foundation Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
WO2000063191A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
JP2002542218A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造および使用
AU3957900A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
WO2000063209A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
WO2000064884A1 (en) 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
EP1105409B1 (en) 1999-05-17 2006-03-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2001264791B2 (en) * 2000-06-16 2006-11-23 Eli Lilly And Company Glucagon-like peptide-1 analogs
ATE297907T1 (de) 2000-07-20 2005-07-15 Hoffmann La Roche Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase- aktivatoren
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
ES2291613T3 (es) 2002-01-16 2008-03-01 Biocompatibles Uk Limited Conjugados de polimeros.
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7314859B2 (en) 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1503283A1 (en) 2003-08-01 2005-02-02 Hewlett-Packard Development Company, L.P. Data processing system and method
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
KR101483917B1 (ko) 2004-11-12 2015-01-16 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20080227691A1 (en) 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
SI1891105T1 (sl) 2005-06-13 2012-07-31 Imp Innovations Ltd Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
AU2006259080A1 (en) 2005-06-15 2006-12-21 Novo Nordisk Health Care Ag Transglutaminase mediated conjugation of growth hormone
BRPI0613984A2 (pt) 2005-07-18 2011-03-01 Novo Nordisk As peptìdios para uso no tratamento da obesidade, seu uso e composição farmacêutica compreendendo os mesmos
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007087711A1 (en) 2006-01-31 2007-08-09 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
MX2008012600A (es) 2006-03-31 2008-12-12 Baxter Int Factor viii pegilado.
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CN101778937A (zh) 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
CN101730739B (zh) 2007-06-15 2013-07-31 加拿大国家研究院 经工程改造的酶活性改善的聚唾液酸转移酶及其用途
EP2190460B1 (en) * 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009033780A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
JP2011503101A (ja) 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
AR072159A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
JP5775450B2 (ja) * 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2987805A3 (en) 2008-08-07 2016-04-13 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
LT2349342T (lt) 2008-10-17 2018-10-10 Baxalta GmbH Modifikuoti kraujo faktoriai, apimantys nedidelį vandenyje tirpaus polimero kiekį
DK2370461T3 (da) 2008-12-15 2013-12-16 Zealand Pharma As Glucagonanaloger
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
MA32970B1 (fr) * 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
JP5635530B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2398822B1 (en) 2009-02-19 2013-01-02 Novo Nordisk A/S Modification of factor viii
BRPI1014508A2 (pt) 2009-06-16 2016-04-05 Univ Indiana Res & Tech Corp análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) * 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2710031B9 (en) 2011-05-18 2018-02-28 Mederis Diabetes, LLC Improved peptide pharmaceuticals for insulin resistance
JP6148228B2 (ja) 2011-05-18 2017-06-14 ユーメデリス ファーマシューティカルズ，インク． 改善されたペプチド製剤
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
MX347703B (es) 2011-06-22 2017-05-09 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1.
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CA2849673A1 (en) * 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych

Also Published As

Publication number Publication date
MY167234A (en) 2018-08-14
AR088161A1 (es) 2014-05-14
EP2758426A1 (en) 2014-07-30
US20130079278A1 (en) 2013-03-28
JP2018021081A (ja) 2018-02-08
CN104093735A (zh) 2014-10-08
ZA201401603B (en) 2015-02-25
US20130288958A1 (en) 2013-10-31
CN104093735B (zh) 2018-07-06
CA2849673A1 (en) 2013-03-28
IL231199A0 (en) 2014-04-30
US8541368B2 (en) 2013-09-24
US20160347812A1 (en) 2016-12-01
AU2012311484A1 (en) 2014-03-06
US20150182594A1 (en) 2015-07-02
JP2014527975A (ja) 2014-10-23
TWI596110B (zh) 2017-08-21
IN2014CN02448A (OSRAM) 2015-06-19
EP2758426B1 (en) 2019-08-07
TW201329102A (zh) 2013-07-16
US9486505B2 (en) 2016-11-08
RU2017101333A (ru) 2018-12-19
WO2013041678A1 (en) 2013-03-28
MX2014003312A (es) 2014-04-25
US9486506B2 (en) 2016-11-08
RU2610175C2 (ru) 2017-02-08
JP6352806B2 (ja) 2018-07-04
KR20140070612A (ko) 2014-06-10
AU2012311484B2 (en) 2017-04-13
RU2014114434A (ru) 2015-10-27
MX354705B (es) 2018-03-16

Similar Documents

Publication Publication Date Title
BR112014006684A2 (pt) análogos de glucagon
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
MX2013011175A (es) Analogos de glucagon novedosos.
BR112015014800A2 (pt) derivados da exendina-4 funcionalizada
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
PH12013500406A1 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
BR112015007685A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/glucagon
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112018011002A2 (pt) variantes de fgf21
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
EA201590011A1 (ru) Пептидные аналоги эксендина-4
BR112015005519A2 (pt) método e sistema para indicar os impactos glicêmicos dos comandos da bomba de infusão de insulina
HK1209633A1 (en) Compositions and methods for treating diabetes
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112015024659A2 (pt) tratamento de diabetes mellitus por formulações de ação prolongada de insulinas
BR112014003704A2 (pt) moduladores ror gama
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
BR112015004012A2 (pt) combinações de inibidores de sglt 2 e fármacos anti-hipertensivos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]